Sabra Healthcare REIT Inc . (NASDAQ:) stock achieved a notable milestone as it reached a 52-week high of $16.89, reflecting a robust performance in the healthcare real estate sector. This peak represents a significant turnaround for the company, which has seen an impressive 1-year change with an increase of 30.82%. Investors have shown increased confidence in Sabra’s portfolio of healthcare-related properties, as the company continues to navigate the challenges and opportunities within the healthcare industry. The 52-week high serves as a testament to Sabra’s strategic initiatives and its resilience in a dynamic market environment.
In other recent news, Sabra Healthcare REIT has seen multiple adjustments in its stock price target. Truist Securities raised the target to $16, anticipating a 16% return on investment, while both Citi and Scotiabank set their targets at $15. These adjustments come amidst Sabra’s stable financial performance, with Truist citing unchanged 2024 and 2025 Net Funds From Operations (NFFO) estimates and both Citi and Scotiabank noting steady funds from operations projections for 2024.
Sabra Healthcare REIT’s annual stockholder meeting resulted in the election of eight board members, ratification of PricewaterhouseCoopers LLP as the independent auditor, and advisory approval of executive compensation. The company has also reported growth in its first-quarter earnings, with skilled nursing EBITDA and coverage surpassing pre-pandemic levels.
Scotiabank anticipates a steady fiscal year 2024 for Sabra, with expected funds from operations per share (FFOPS) growth of approximately 5% year over year. Additionally, the company plans to engage in accretive acquisitions later in the year, which are not yet factored into the management’s guidance. These are recent developments that investors should take into account when considering Sabra Healthcare REIT.
InvestingPro Insights
As Sabra Healthcare REIT Inc. (SBRA) touches a 52-week high, a closer look at InvestingPro data reveals a company poised for growth with a solid investment profile. The real-time data shows Sabra with a market capitalization of approximately $3.9 billion, indicating a substantial presence in the healthcare real estate sector. The company’s P/E ratio stands at 78.74, which adjusts to a more attractive 36.59 when considering the last twelve months leading up to Q1 2024. This adjustment reflects the company’s expected earnings growth, aligning with the InvestingPro Tip that net income is expected to grow this year. Furthermore, Sabra’s revenue has seen a healthy increase of 21.68% over the last twelve months as of Q1 2024, underscoring its robust financial performance.
An important aspect for income-focused investors is the company’s dividend yield, which currently stands at an appealing 7.28%. This is complemented by the fact that Sabra has maintained dividend payments for 14 consecutive years, a testament to its financial stability and commitment to shareholder returns. Additionally, the company’s shares are trading near their 52-week high, with a price that is 99.7% of this peak, signaling strong market sentiment.
For those interested in a deeper analysis, InvestingPro offers additional insights, including 9 more InvestingPro Tips to help investors make informed decisions. These tips are available at: https://www.investing.com/pro/SBRA. With the next earnings date on the horizon for August 7, 2024, potential investors have ample opportunity to explore the comprehensive data and expert tips provided by InvestingPro to gauge the future trajectory of Sabra Healthcare REIT Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.